Sphera Funds Management’s Viking Therapeutics VKTX Stock Holding History

Sphera Funds Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-83,270	Closed	-$2.01M	–	133
2025 Q1	$2.01M	Sell	83,270 -20,000	-19%	-$632K	0.46%	66
2024 Q4	$4.16M	Sell	103,270 -29,796	-22%	-$1.7M	0.75%	50
2024 Q3	$8.42M	Buy	+133,066	New	+$7.81M	1.34%	22
2020 Q3	–	Sell	-205,000	Closed	-$1.48M	–	115
2020 Q2	$1.48M	Sell	205,000 -385,000	-65%	-$2.56M	0.14%	77
2020 Q1	$2.76M	Hold	590,000	–	–	0.35%	46
2019 Q4	$4.73M	Buy	+590,000	New	+$4.3M	0.39%	58
2019 Q1	–	Sell	-745,727	Closed	-$5.71M	–	121
2018 Q4	$5.71M	Sell	745,727 -114,000	-13%	-$1.36M	0.64%	38
2018 Q3	$15M	Buy	859,727 +77,303	+10%	+$920K	1.72%	11
2018 Q2	$7.42M	Sell	782,424 -809,992	-51%	-$5.39M	1.02%	22
2018 Q1	$6.96M	Sell	1,592,416 -552,884	-26%	-$3.06M	1.06%	25
2017 Q4	$8.71M	Buy	2,145,300 +1,855,300	+640%	+$5.39M	1.02%	21
2017 Q3	$554K	Buy	+290,000	New	+$329K	0.08%	110

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Sphera Funds Management's VKTX Position: Q2 2025 in Review

Sphera Funds Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 83,270 shares — an estimated $2.01M sold.

Sphera Funds Management first reported a position in VKTX in Q3 2017 and held it in 12 quarters. The position peaked at $15M in Q3 2018. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Sphera Funds Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Sphera Funds Management sold 83,270 Viking Therapeutics shares in Q2 2025, an estimated $2.01M.
Sphera Funds Management first reported a position in Viking Therapeutics in Q3 2017 and held it in 12 quarters.
Sphera Funds Management's Viking Therapeutics position peaked at $15M in Q3 2018.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.